...
首页> 外文期刊>Bioorganic and Medicinal Chemistry Letters >Structural basis for the selective inhibition of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) by a selenium-containing inhibitor with chloro-aminopyridine as a basic group
【24h】

Structural basis for the selective inhibition of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) by a selenium-containing inhibitor with chloro-aminopyridine as a basic group

机译:用氯氨基吡啶含氯氨基吡啶作为碱性抑制剂选择性凝血酶活性纤维蛋白分解抑制剂(TAFIA)的结构基础

获取原文
获取原文并翻译 | 示例
           

摘要

Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) is a target molecule for treating thromboembolic disorders. We previously reported that design and synthesis of compound 1 containing a selenol group and chloloaminopyridine. Compound 1 showed high inhibitory activity towards TAFIa, with a high degree of selectivity for TAFIa over carboxypeptidase N (CPN). Here we report investigation of this selectivity. To obtain co-crystal of 1/pp-CPB (a surrogate of TAFIa), we synthesized protected compound 5 as a stabilized precursor of 1. The X-ray crystal structure and docking study indicated that the Cl substituent is accommodated in the pp-CPB specific pocket whereas CPN has no identical pocket. This is important information for the design of drugs targeting TAFIa with high selectivity.
机译:活性凝血酶可活化的纤维蛋白溶解抑制剂(TAFIA)是用于治疗血栓栓塞障碍的靶分子。 我们之前报道的是,含有Selenol基团和氯氰胺吡啶的化合物1的设计和合成。 化合物1显示出对Tafia的高抑制活性,对羧肽酶N(CPN)的TAFIA具有高度选择性。 在这里,我们报告了对这种选择性的调查。 为了获得1 / PP-CPB的共晶(TAFIA的替代),我们合成保护化合物5作为1. X射线晶体结构和对接研究表明CL取代基被容纳在PP-中 CPB特定口袋,而CPN没有相同的口袋。 这是针对Tafia的药物设计具有高选择性的重要信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号